Creative Biolabs, a world-leading service provider of antibody generation and development, has established a series of in vitro diagnostic (IVD) antibody development services for diagnostic uses, which are available for clients worldwide. Our scientific group focused on IVD antibody development is pleased to assist you in your projects with a timely and cost-effective way.
hMLH1 Marker
hMLH1, also called MutL homolog 1, is a key DNA mismatch repair (MMR) protein encoded by human MLH1 gene located on Chromosome 3. MLH1 gene is a human homolog of the E. coli DNA mismatch repair gene (mutL), which mediates protein-protein interactions during mismatch recognition, strand removal, and strand discrimination. MLH1 protein is one constituent of a set of seven DNA mismatch repair (MMR) proteins, which work coordinately in sequential steps to initiate the DNA mismatch repairs in humans. There are seven MMR proteins in humans, including MLH1, MLH3, MSH2, MSH3, MSH6, PMS1 and PMS2. MLH1 protein can heterodimerize with PMS2 (a mismatch repair endonuclease) to form MutL alpha (MLH1-PMS2). MutL alpha (MLH1-PMS2) interacts physically with the clamp loader subunits of DNA polymerase III, indicating that it likely contributes to recruiting the DNA polymerase III to the site of the MMR.
Fig.1 Mechanism of canonical mismatch repair. (D Heinen., 2014)
The Role of hMLH1 in Ovarian Cancer
Defects of mismatch repair (MMR) capacity that arises through genetic and/or epigenetic mechanisms have been supposed to be an important tumor initiating mechanism in ovarian cancer. Genetic mechanisms of MMR dys-function include somatic and germline mutations in the MMR proteins. Germline mutations normally lead to hereditary nonpolyposis colorectal cancer (HNPCC), which is the third most common cause of inherited ovarian cancer after BRCA1 and BRCA2 mutations. MLH1 promoter hypermethylation is an epigenetic mechanism supposed to result in inactivation of the MMR system. Studies have shown that MLH1 promoter hypermethylation is observed in a considerable proportion of ovarian cancers, especially those with MSI-H (Microsatellite Instability-High). The acquired loss of MLH1 expression caused by treatment was reported to be correlated with improved survival.
Antibodies are core elements for antibody-based immunoassays for detecting and quantifying antigens of interest in all kinds of samples such as serum, urine, and tissue preparations. With advanced technology and years of experience, Creative Biolabs has launched a whole series of hMLH1-specific antibody development services for the diagnosis and prognosis of ovarian cancer. Additionally, Creative Biolabs also provides diagnostic immunoassay development services targeting this marker. We offer one-stop services from antibody generation to kit manufacture. If you are interested in our services, please feel free to contact us for more details.
Reference
For Research Use Only.
